Скачать
Praxis Medicines Emerald Study Community Meeting for the CACNA1A Community
Автор: CACNA1A Foundation
Загружено: 2025-11-21
Просмотров: 22
Описание:
Praxis Medicines is enrolling participants in a clinical trial for Relutrigine, a new add-on therapy designed to reduce seizures in individuals with Dravet syndrome or genetic epilepsies—including CACNA1A. The trial is open to individuals ages 2 to 65 and offers flexible participation options: fully remote, in-clinic, or hybrid. A total of 165 people with DEE will be enrolled from the U.S., Europe, Australia, and South America. Key eligibility criteria include at least 4 motor (movement-related) seizures within the 4 weeks preceding screening. This video explains the study in detail.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
